Bioceres Crop Solutions Corp.

Good afternoon, ladies and gentlemen. Thank you for joining today's BioSeries Crop Solutions Fiscal Second Quarter 2024 Fiscal Resorts Conference Call. My name is Tia, and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question, please press star one on your telephone keypad. I would now like to pass the call over to Paula Cervantes, Head of Investor Relations at Bayer Series Crop Solutions. Please proceed.

Good afternoon, and thank you everyone for joining our second quarter fiscal 24 earnings call. Today's presentation will be led by our Chief Executive Officer, Federico Trucco, and our Chief Financial Officer, Enrique Lopez-Pecube. Both of them will be available for the Q&A session following the presentation. Before we proceed, I would like to make the following safe harbor statement. Today's call will contain forward-looking statements, and I refer you to the forward-looking statement section of the earnings release and presentation, as well as the recent filings with the SEC. We assume no obligation to update or revise any forward-looking statements to reflect new or changed circumstances. This conference call is being webcast, and the webcast link is available at Biocera's Crop Solutions Investor Relations website. I will now turn the call over to our CEO, Federico Trucco, to begin our presentation. Thank you.

Thank you, Paula, and thanks, everyone, for joining. Good afternoon or good evening, depending on where you are. It's a pleasure to be having our earnings call today. Please turn to slide number three for this call's highlights. I would like to start by expressing our profound gratitude to our customers, our partners, and the entire BioCities team, from manufacturing to R&D to sales and so on, for what has been a new record-setting quarter. While we are not immune to the broader destocking process in several geographies, resulting in a double-digit contraction in some key markets like Brazil, our portfolio of innovative products, secular growth drivers, and strong execution by our commercial teams allowed us to continue to outperform the industry and deliver our highest quarterly revenues yet. Total revenues in our second quarter of fiscal 24 were $140 million, an almost 50% improvement compared to the same quarter of last year. Our net income improved by eightfold and our adjusted EBITDA for the quarter reached 24.1 million, a 134% increase compared to the year-ago period, resulting in an LTM EBITDA of 86.7 million. In a minute, Enrique will provide further details on this outstanding financial performance. On the HB4 front, we continue to make good progress as I will briefly discuss towards the end of the presentation. It is important to note that we have completed last season's wheat harvest and jointly with our multipliers have the required inventories to meet our fiscal year guidance. Another important recent development was the granting of a new patent from the USPTO covering the HP4 soy technology and initiating our third patent family for this product, which will provide protection for our seats until 2042. I will now pass the presentation over to Enrique for a more detailed discussion of our numbers.